TY - JOUR
T1 - It might be a dead end
T2 - immune checkpoint inhibitor therapy in EGFR-mutated NSCLC
AU - Akao, Ken
AU - Oya, Yuko
AU - Sato, Takaya
AU - Ikeda, Aki
AU - Horiguchi, Tomoya
AU - Goto, Yasuhiro
AU - Hashimoto, Naozumi
AU - Kondo, Masashi
AU - Imaizumi, Kazuyoshi
N1 - Publisher Copyright:
© The Author(s) 2024.
PY - 2024
Y1 - 2024
N2 - Despite innovative advances in molecular targeted therapy, treatment strategies using immune checkpoint inhibitors (ICIs) for epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) have not progressed significantly. Accumulating evidence suggests that ICI chemotherapy is inadequate in this population. Biomarkers of ICI therapy, such as programmed cell death ligand 1 (PD-L1) and tumor-infiltrating lymphocytes (TILs), are not biomarkers in patients with EGFR mutations, and the specificity of the tumor microenvironment has been suggested as the reason for this. Combination therapy with PD-L1 and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors is a concern because of its severe toxicity and limited efficacy. However, early-stage NSCLC may differ from advanced-stage NSCLC. In this review, we comprehensively review the current evidence and summarize the potential of ICI therapy in patients with EGFR mutations after acquiring resistance to treatment with EGFR-tyrosine kinase inhibitors (TKIs) with no T790M mutation or whose disease has progressed on osimertinib.
AB - Despite innovative advances in molecular targeted therapy, treatment strategies using immune checkpoint inhibitors (ICIs) for epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) have not progressed significantly. Accumulating evidence suggests that ICI chemotherapy is inadequate in this population. Biomarkers of ICI therapy, such as programmed cell death ligand 1 (PD-L1) and tumor-infiltrating lymphocytes (TILs), are not biomarkers in patients with EGFR mutations, and the specificity of the tumor microenvironment has been suggested as the reason for this. Combination therapy with PD-L1 and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors is a concern because of its severe toxicity and limited efficacy. However, early-stage NSCLC may differ from advanced-stage NSCLC. In this review, we comprehensively review the current evidence and summarize the potential of ICI therapy in patients with EGFR mutations after acquiring resistance to treatment with EGFR-tyrosine kinase inhibitors (TKIs) with no T790M mutation or whose disease has progressed on osimertinib.
UR - http://www.scopus.com/inward/record.url?scp=85199298315&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85199298315&partnerID=8YFLogxK
U2 - 10.37349/etat.2024.00251
DO - 10.37349/etat.2024.00251
M3 - Review article
AN - SCOPUS:85199298315
SN - 2692-3114
VL - 5
SP - 826
EP - 840
JO - Exploration of Targeted Anti-tumor Therapy
JF - Exploration of Targeted Anti-tumor Therapy
IS - 4
ER -